NCT04002947
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
At risk: Primary completion moved at least 4 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 218 versions: 5 with changes below, 45 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Primary completion pushed from May 31, 2027 to Oct 12, 2027
- Notable Eligibility criteria expanded, about 32 words
- Notable Primary completion pushed from May 31, 2026 to May 31, 2027
- Study completion pushed from Mar 31, 2030 to Mar 31, 2031
- Notable Primary completion date: May 31, 2025 to May 31, 2026
- Study completion date: Mar 31, 2029 to Mar 31, 2030
- Study Status, Eligibilityv169
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Response rate
Timeframe: every 2 cycles
Secondary (5)
Safety and tolerability
Progression-free survival
Overall survival
Event-free survival
Complete response rate
Arms and interventions
1Experimental
Acalabrutinib 100 mg orally twice a day for 14 days; Following window: patients with \> or = to 25% tumor reduction, treat with DA-EPOCH-R or R-CHOP + acalabrutinib 100mg orally twice a day for the first 10 days, for 6 cycles; whereas, patients with \<25% tumor reduction, treat with DA-EPOCH-R or R-CHOP alone for 6 cycles
Drugs: DA-EPOCH, CHOP, Acalabrutinib
Biologicals: Rituximab
Sites
1 site in 1 country
- National Institutes of Health Clinical CenterBethesda, Maryland, United States